

# **Supporting Information**

## **Homology modeling of human UDP-glucuronosyltransferase 1A6 reveals insights into factors influencing substrate and co-substrate binding**


*Alexander D. Smith, Brent D.G. Page, Abby C. Collier, and Michael W.H. Coughtrie\**

Faculty of Pharmaceutical Sciences, The University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, CANADA


\*E-mail: michael.coughtrie@ubc.ca.

### **Table of Contents**

1. Figure S1	S2	19. Table S4	S19
2. Figure S2	S3	20. Table S5	S20
3. Figure S3	S4	21. Table S6	S21-S24
4. Figure S4	S5	22. Table S7	S24
5. Figure S5	S6	23. Table S8	S25
6. Figure S6	S7	24. Table S9	S26-S27
7. Figure S7	S8	25. Table S10	S28-S31
8. Figure S8	S9	26. Table S11	S31
9. Figure S9	S10	27. Table S12	S32
10. Figure S10	S11	28. Table S13	S33-S34
11. Figure S11	S12	29. Table S14	S35
12. Figure S12	S13	30. Table S15	S36
13. Figure S13	S14	31. Table S16	S37
14. Figure S14	S15	32. Table S17	S38
15. Figure S15	S16	33. Table S18	S39-S40
16. Table S1	S17	34. Table S19	S41
17. Table S2	S17	35. References	S42-S45
18. Table S3	S18		



**Figure S1.** The 5 models produced by I-TASSER for each input condition are shown aligned with the UGT2B7 crystal structure (PDB 2O6L) in yellow, and the final UGT1A6 model in light blue. Model 1 is shown in red, model 2 in orange, model 3 in green, model 4 in blue, and model 5 in purple. A. Models generated with the signal peptide and without the UGT2B7 crystal structure as a guiding template (WSNT), B. Without the signal peptide, and without the UGT2B7 crystal structure (NSNT), C. With the signal peptide, and with the UGT2B7 crystal structure as a guide (WSWT), D. Without the signal peptide and with the UGT2B7 crystal structure as a guide (NSWT). Structural alignments in .mol2 format are in the “Supplemental structures” zip file (I-TASSER aligned models folder).




**Figure S2.** Ramachandran plot of the final UGT1A6 homology model.






**B**


2O6L	285	-----AKPLPKEXEDFVQSSGENGVVVFSL	309
UGT1A6	267	VMPNMVFIGGINCKKRKDLSQEFFFAYINASGEHGIVVFSL	306
2O6L	310	GSXVSNKTEERANVIASALAQIPQKVWLWEDGNKPDTLGL	349
UGT1A6	307	GSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLAN	346
2O6L	350	NTRLYKWIHQNDLLGHHPKTRAFFITHGGANGIYEAIYHGP	389
UGT1A6	347	NTILVKWLPQNDLLGHHPMTRAFFITHAGSHGVYESICNGVP	386
2O6L	390	XVGIPLFADQPDNIAHXKARGAAVRVDFNFXSTDLLNAL	429
UGT1A6	387	MVMMPLFGDQMDNAKRMETKGAGVTILNVLEMITSEDLENAL	426
2O6L	430	KRVINDPSYKENVXKLS-----	446
UGT1A6	427	KAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMR	443




**Figure S3.** Alignment of the final UGT1A6 model with the template UGT2B7 crystal structure (2O6L). **A.** Final refined homology model of UGT1A6 with overlaid UGT2B7 crystal structure. Helices are shown as spirals, and  $\beta$ -sheets are shown as broad ribbons. The C-terminal domain (blue) is shown at the top, with the N-terminal domain (green) shown at the bottom of the image. The envelope helices (magenta) are shown to the left, with the transmembrane domain (purple) at the bottom. The putative dimerization domain (PDPVSYIPRCY) of UGT1A6 is highlighted in orange. The UGT2B7 crystal structure is shown in yellow. **B.** Protein sequence alignment of the aligned regions of the UGT1A6 model with UGT2B7 (2O6L) crystal structure. Residues with RMSDs differing by  $>2 \text{ \AA}$  are highlighted in red boxes. Amino acid 'X' in the 2O6L sequence correspond to selenomethionine. **C.** Graph of RMSD values over the length of the aligned proteins. The structural alignment can be found in the "supplemental structures" zip file, file UGT1A6\_2B7\_alignment.mol2.




**Figure S4.** Structural alignments of the final UGT1A6 model with A. both 2ACV and 5TME GT structures, B. 2ACV alone, C. 5TME alone. Structures are coloured according to amino acid similarity: dark teal, identical; blue, strong similarity; cyan, weak similarity. Residues in red have RMSDs > 2 Å, and residues in orange failed to align. UDPGA is shown in its binding site. D. Graph of RMSD values over the length of the aligned UGT1A6 and 2ACV amino acids. E. Graph of RMSD values over the length of the aligned UGT1A6 and 5TME amino acids. F. Sequence alignments generated from the superimposed protein structures. Amino acid similarity shading is as in A, strongly similar amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, and FYW; weakly similar amino acids: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, FVLIM, and HFY. The structural alignments between our UGT1A6 model and all GTs can be found in the “Supplemental structures” zip file, file UGT1A6\_all\_alignments.mol2.




**Figure S5.** Comparison of our UGT1A6 model with that of Ghemtio *et al* (2014), which has been recapitulated from the coordinates supplied in that paper's supplementary information<sup>1</sup>. A. Structural overlay of both models, coloured by RMSD, with closely aligning regions in green, and more widely deviating regions in magenta. The co-substrates, UDPGA (our model) and U2F (Ghemtio *et al* model) are overlaid in the co-substrate binding region. Quercetin is shown in the substrate binding area in our model. B. Graph of RMSD values over the length of the aligned sequences. C. Graph of RMSD values for our UGT1A6 model, the Ghemtio *et al* model, and the 5 template structures used to create the Ghemtio *et al* model, over the length of alignment generated from the superimposed proteins.




**Figure S6.** Comparison of UDPGA top docking positions into various mutated UGT1A6 models. Mutations are shown in order from most to least severe effect on UDPGA binding compared to the wild-type enzyme. A. Wild-type UGT1A6, B. G376A mutant, C. S37A mutant, D. W353A mutant, E. H38A mutant, F. R172A mutant, G. H375A mutant, H. S308A mutant, I. F393A mutant. Mutated residues are highlighted in cyan, quercetin (Que) is shown docked into the substrate binding site.




**Figure S7.** Comparison of the docking of selected substrates into the wildtype and mutated UGT1A6 model. The observed interactions for each docked compound are indicated. Interactions are coloured according to type with electrostatic interactions shown in orange, classical hydrogen bonds in dark green, non-classical hydrogen bonds in pale green,  $\pi$ - $\pi$  stacking interactions in dark pink,  $\pi$ -alkyl interactions in light pink, and unfavourable interactions in red. Residues with multiple colours had multiple different interactions with the substrate.




**Figure S8.** Comparison of the docking of three small planar phenolic compounds into two mutations that contribute to several UGT1A6 polymorphisms. The observed interactions for each docked compound are indicated, and coloured as in Figure S7. 4NP, 4-Nitrophenol; 5HT, serotonin; APAP, acetaminophen.




**Figure S9.** Root mean square fluctuation (RMSF) for each residue over the course of the molecular dynamics simulation.




**Figure S10.** Snapshots from the molecular dynamics simulation trajectory. The cartoon diagram is coloured as in Figure S3, with the helices and sheets that showed substantial differences coloured separately. The bound UDPGA co-substrate, and bound substrate quercetin are shown as sticks. N $\beta$ 2, N $\alpha$ 2, and N $\beta$ 3 are shown in red, N $\alpha$ 3-1 in bright orange, N $\alpha$ 3-3 in yellow, N $\alpha$ 5-2 in bright green, C $\alpha$ 0 in teal, and C $\beta$  – C $\alpha$ 3 in purple.




**Figure S11.** Shifts in the CTD following 20 ns of simulation compared to the initial structure. The initial (0 ns) structure is overlaid with the structure after 50 ns of simulation time. A. Shifts in the C $\alpha$ 0 helix. B. Shifts in the C $\beta$ 3 sheet and C $\alpha$ 3 helix. The shifted residues are highlighted in teal (0 ns) and orange (50 ns).




**Figure S12.** Changes in the UDPGA-UGT1A6 interacting residues following 50 ns of molecular dynamics simulations. Interacting residues are coloured as in Figure S7.



**Figure S13.** Shifts in the NTD following 50 ns of simulation. The initial (0 ns) structure is overlaid with the structure after 50 ns of simulation time. Secondary structures are highlighted using blues for the 0 ns time point, and oranges for the 50 ns snapshot. A. Shift in the N $\beta$ 2 (teal or orange), N $\alpha$ 2 (royal blue and bright orange), and N $\beta$ 3 region (cornflower blue and dark orange). B. Shifts in the N $\alpha$ 3-1 and N $\alpha$ 3-2 regions, C. Shifts in the N $\alpha$ 3-3 (teal or orange) and N $\beta$ 4 region (cornflower blue or dark orange). D. Shifts in the N $\alpha$ 5-2 region.



**Figure S14.** Changes in the quercetin-UGT1A6 interacting residues following 50 ns of molecular dynamics simulations. Interacting residues are coloured as in Figure S7, water-hydrogen bonds are shown in blue.



**Figure S15.** Distances between the N $\varepsilon$ 2 group of the catalytic H38, the glucuronic acid C1', and the potentially glucuronidated hydroxyl groups of the bound quercetin ligand over 50 ns of molecular dynamics simulations. Distances between the 3'-OH and N $\varepsilon$ 2 are shown in red, and with the C1' in green; distances between the 4'-OH and N $\varepsilon$ 2 in pink, and C1' in cyan; distance between the 3-OH and N $\varepsilon$ 2 in orange, and C1' in blue; and the distance between the 7-OH and N $\varepsilon$ 2 in yellow, and C1' in purple.

**Table S1.** Confidence scores for each model produced by I-TASSER

Input	Model #	C-Score <sup>a</sup>	Est. TM-Score <sup>b</sup>	Est RMSD (Å) <sup>c</sup>	No. of decoys <sup>e</sup>	Cluster density <sup>f</sup>
WSNT	1	-1.65	0.51 ± 0.15	11.4 ± 4.5	910	0.0591
	2	-2.53			456	0.0247
	3	-2.56			422	0.0239
	4	-2.6			340	0.0229
	5	-3.07			194	0.0144
NSNT	1	-1.67	0.51 ± 0.15	11.3 ± 4.5	805	0.0575
	2	-1.49 <sup>g</sup>			630	0.0691
	3	-1.95			600	0.0436
	4	-2.64			291	0.0218
	5	-3.32			180	0.011
WSWT	1	-2.29	0.45 ± 0.14	13.0 ± 4.2	1169	0.0277
	2	-3.06			494	0.0128
	3	-3.09			493	0.0124
	4	-3.05			470	0.013
	5	-3.73			268	0.0065
NSWT	1	-1.65	0.51 ± 0.15	11.2 ± 4.6	2262	0.0518
	2	-3.04			597	0.0129
	3	-3.22			483	0.0108
	4	-3.13			463	0.0118
	5	-3.33			450	0.0097

<sup>a</sup>C-scores can range from -5 to 2, with higher values indicating higher confidence; <sup>b</sup>I-TASSER only provides TM-scores for the top ranked model, scores >0.5 indicating a model of correct topology and scores <0.17 meaning random similarity; <sup>c</sup>RMSD scores are only provided for the top ranked model, with local errors; <sup>d</sup>the number of low-temperature model replicas generated by excising continuous fragments from the threading alignments and reassembly through replica-exchanged Monte Carlo simulations; <sup>e</sup>the number of structure decoys at a unit of space in the SPICKER cluster, higher cluster density signifies a higher quality model with the structure occurring more frequently in the simulation; <sup>g</sup>models are ranked by cluster size, and although lower ranked models occasionally have higher C-scores, the top ranked model is usually better.

**Table S2.** DOPE and verify protein scores for I-TASSER produced models

Model	DOPE score	Normalized DOPE score*	Verify score	Verify expected high score	Verify expected low score
WSNT	-60317.38	-0.00	158.84	243.19	109.44
NSNT	-58504.77	-0.33	144.49	231.22	104.05
WSWT	-63160.52	-0.38	160.52	243.19	109.44
NSWT	-60440.23	-0.60	173.76	231.22	104.05
2O6L	-37114.25	-1.99	161.43	149.36	67.21
2ACW	-63436.67	-2.12	256.69	210.496	94.7231

\*This is a Z-score derived from the DOPE score that accounts for protein size.

**Table S3.** Root Mean Square Distances (RMSD) between UGT1A6 models and GT crystal structures

Structure	WSNT (Å)	NSNT (Å)	WSWT (Å)	NSWT (Å)
1IIR	1.944	1.739	1.588	1.59
1PN3	2.331	2.164	1.807	1.782
1PNV	2.304	2.135	1.822	1.799
1RRV	2.102	1.942	1.477	1.491
2ACV	1.487	1.504	1.36	1.497
2ACW	1.463	1.484	1.365	1.457
2C9Z	1.605	1.625	1.608	1.65
2IYA	2.061	1.901	1.743	1.763
2O6L	1.283	1.318	0.841	0.793
2P6P	2.014	1.834	1.705	1.68
2PQ6	1.426	1.42	1.991	1.904
2VCE	1.601	1.617	1.904	1.828
2VCH	1.625	1.641	2.017	1.907
2VG8	1.605	1.622	2.027	1.919
3D0R	2.075	1.867	2.14	2.133
3H4I	2.412	2.226	1.839	1.86
3H4T	2.421	2.236	1.844	1.869
3HBF	1.446	1.467	1.868	2.03
3HBJ	1.452	1.464	1.915	2.103
3IA7	2.311	2.233	2.006	2.01
3OTG	1.984	1.866	1.489	1.452
3OTH	2.007	1.877	1.508	1.47
3RSC	1.95	1.786	1.713	1.695
3WC4	1.325	1.316	1.783	1.981
4REL	1.323	1.316	1.747	1.945
4REM	1.341	1.332	1.685	1.831
4WHM	1.313	1.306	1.628	1.737
5TMB	1.368	1.401	1.798	1.726
5TME	1.41	1.431	1.858	1.756
5U6M	1.415	1.436	1.586	1.549
WSNT		1.283	1.182	1.111
NSNT			1.247	1.168
WSWT				1.338

**Table S4.** Residues important for co-substrate binding in multiple GT structures

UDPGA moiety	UGT1A6 Residue (U2F)	Crystal structure (bound co-substrate)																						
		2C1Z (U2F)	2VCE (U2F)	3H4I (U2F)	2ACW (UDPG)	5GL5 (UDPG)	2ACV (UDP)	2C1X (UDP)	2C9Z (UDP)	2IYA (UDP)	2VCH (UDP)	2VG8 (UDP)	3H4T (UDP)	3HBF (UDP)	3HBJ (UDP)	4WHM (UDP)	5TMB (UDP)	5TME (UDP)	5U6M (UDP)	1PN3 (TYD)	1PNV (TYD)	1RRV (TYD)	3OTG (TYD)	3OTH (TYD)
Glucose	G36*			S10																				
Glucose	H38*	H20		D13		D752																		
Glucose	R172*	T141																						
Glucose	S374	W353	W367	A294	W360	S1072																		
Glucose	D395	D374	E388	D315	E381	D1093																		
Glucose	Q396	Q375	Q389	Q316	Q382	Q1094																		
Beta phosphate	G36*		S10	S749	S18		S10,R11													T10				
Beta phosphate	S37*	T19		G12	G751	G21	T19	T19	G24	G18	G18	R11,G12	T25	T25	S16		G17	R11,G12	G12	G12	G12	G12		
Beta phosphate	G307*	G279				G284				S277												G236		
Beta phosphate	S308*	T280		S230	S285	S285	T280	T280	S277	S277	S230	S282	S282	T273	T291	T291	S273	S230	S230	S246	T231	T231		
Beta phosphate	M309*																			S232		T238		
Beta phosphate	G373										G293									S311		G303		
Beta phosphate	H375						G332																	
Beta phosphate	G376						S333																	
Beta phosphate	F393		Y386		Y379			Y386	Y386															
Alpha phosphate	S37*				G21		G24	G18	G18		T25	T25			G26					G12	G12			
Alpha phosphate	G307*																					G236		
Alpha phosphate	S308*						S264																	
Alpha phosphate	H371	H350	H364		H357	H357	H357	H350	H350	H328	H364	H364	H352	H352	H343		H361	H342				H301		
Alpha phosphate	G373						G352		G332								S295	S295						
Alpha phosphate	S374			S1072						W367	W367								G313	S298	S298			
Alpha phosphate	H375	N354	N368	G295	N361	G1073	N361	N354	N354	N368	N368	G295	N356	N356	N347	N365	N365	N346		G313	G299	G299		
Alpha phosphate	G376	S355	S369	T296	S362	T1074	S362	S355	S355	S369	S369	T296	S357	S357	S348	S366	S366	S347	T298	T298	T314	T300	T306	
(deoxy)Ribose	S37*			R750		T19																		
(deoxy)Ribose	L40*						N27																	
(deoxy)Ribose	N357*		H278		H1056					H278														
(deoxy)Ribose	E379	E358	E372		E365	E365	E358	E358	E336	E373	E372		E360	E360	E351	E369	E369	E350				E309		
Pyrimidine ring	S37*		G18	R11		R750													R11	R11				
Pyrimidine ring	R282*								Q245										R207					
Pyrimidine ring	K283*																					L218		
Pyrimidine ring	S305*			C282		C282							C270			A270								
Pyrimidine ring	R335	S306			N1025		S306	S290				S308	S308								A257	A257		
Pyrimidine ring	W353	W332	W346		W339	W339	W332	W332	W312	W346	W346	W334	W334	W325	F343		W324				W279	W279	W285	
Pyrimidine ring	L354	A333	A347	E275	A340	A340	A333	A333	V313	A347	A347	E275	A335	A335	V326	C344	S325	E277	E277	E293	V280	V280	V286	
Pyrimidine ring	P355*		V276		V1054					V276								V278	V278	V294				
Pyrimidine ring	Q356					Q335									Q346		L280	L280	F296			H288		
Pyrimidine ring	N357		H278		H1056				H278															

\*: residue present within a loop region, TYD: Thymidine-5'-diphosphate, UDP: Uridine-5'-diphosphate, UDPG: Uridine-5'-diphosphate-alpha-D-glucose, U2F: Uridine-5'-diphosphate-2-deoxy-2-fluoro-alpha-D-glucose.

**Table S5.** UDPGA docking site mutagenesis

Importance	Mutation	-CDOCKER score (kcal mol <sup>-1</sup> )	UDPGA Conformation	RMSD from original pose (Å)
Co-substrate binding	S37A	65.6863	reversed linear	10.3539
Catalytic	H38A	51.9961	curved	6.6236
Catalytic	D150A	60.8324	linear	0.0095
Co-substrate and substrate binding	R172A	69.0987	curved	2.9425
Polymorphism	T181A	59.9712	linear	0.0007
Polymorphism	R184S	59.8607	linear	0.0280
Co-substrate binding	S308A	56.5551	slight curve	1.3158
Co-substrate binding	W353A	64.6337	reversed curved	10.0896
Co-substrate binding	L354A	58.6522	linear	0.2295
Co-substrate binding	H375A	60.6102	curved	2.9239
Co-substrate binding	G376A	42.7748	reversed curved	11.1750
Co-substrate and substrate binding	F393A	63.0931	linear	0.3093

**Table S6.** Substrates, docking scores, and enzyme kinetic data

Substrate (PubChem ID)	-CDOCKER Energy (kcal mol <sup>-1</sup> ); Molecular weight (g mol <sup>-1</sup> )	Metabolism <i>K<sub>m</sub>/S<sub>50</sub></i> (μM)	Reference	Rationale
(+)-Catechin (9064)	52.7769; 290.27	ND	2	Catechin, plant substrate
		3.36 ± 0.134 <sup>a,c</sup>	3	
		78 <sup>b,g</sup>	4	
		67 <sup>a,g</sup>		
1-Naphthol (7005)	6.26024; 144.173	84 ± 7 <sup>a,c</sup> 74 ± 7 <sup>b,c</sup>	5	Naphthol, UGT1A6 substrate
		3.1 ± 0.02 <sup>b,d</sup>	6	
		8.07 ± 0.48 <sup>a,c</sup>	7	
		5.25 ± 0.23 <sup>a,c,p</sup>		
2,4,5-Trichlorophenol (7271)	34.6477; 197.439	Unknown	8	Plant UGT72B1 substrate
4-Hydroxytamoxifen (449459)	15.0642; 387.523	ND	9	Tamoxifen metabolite, other UGT substrate
4-Hydroxywarfarin (54682146)	49.4215; 324.332	ND	10	Coumarin, other UGT substrate
4-Methylumbelliferon (5280567)	40.2052; 176.171	120 ± 10 <sup>a,f</sup> 109 ± 3.7 <sup>b,d</sup> 76.4 ± 15.1 <sup>a,c</sup> 57.5 ± 2 <sup>a,c</sup>	11 6 7	
4-Nitrophenol (980)	36.5691; 139.11	770 ± 60 <sup>a,d</sup> 730 ± 80 <sup>a,d,o</sup> 644 ± 22 <sup>a,c</sup> 1100 ± 230 <sup>a,d</sup> 730 ± 150 <sup>a,d,l</sup> 570 ± 290 <sup>a,d,m</sup> 450 ± 160 <sup>a,d,n</sup> 595 ± 140 <sup>a,g</sup>	12 3 13 14	UGT1A6 substrate
Acetaminophen (1983)	22.298; 151.165	2200 ± 50 <sup>a,d</sup> 2200 ± 300 <sup>a,c</sup> 4000 ± 400 <sup>a,c</sup>	15 16 17	Phenolic drug, UGT1A6 substrate
Alvocidib/Flavopiridol (5287969)	47.7067; 401.843	ND	18	Synthetic flavonoid, other UGT substrate
Apigenin (5280443)	64.9334; 270.24	Minimal (rate: 0.4 nmol/min/mg) Minimal	19 20	Flavone, plant substrate & poor UGT1A6 substrate
Aspirin (2244)	32.5819; 180.159	ND	21	Non-metabolized control
Bilirubin (5280352)	39.7054; 584.673	ND	21	Non-metabolized control
Bilirubin Diglucuronide (5459911)	---; 936.328	---		Non-metabolized control

Bilirubin monoglucuronide (5459858)	10.6641; 760.797	---		Non-metabolized control
Biochanin A (5280373)	45.1212; 284.267	Minimal	22	Isoflavone, plant substrate
Bisphenol A (6623)	22.2207; 228.291	ND	23	Plant substrate
Chrysin (5281607)	50.0525; 254.241	12 <sup>a,c</sup>	24	Flavone, plant substrate & poor UGT1A6 substrate
		12.8 <sup>a,e</sup>	25	
		Minimal	20	
<i>cis</i> -Resveratrol (1548910)	42.4312; 228.247	402.1 ± 39.2 <sup>a,d</sup>		Stilbene, UGT1A6 substrate
		749.8 ± 61.2 <sup>a,d,l</sup>		
		376 ± 28.8 <sup>a,d,m</sup>	26	
		945.2 ± 93.5 <sup>a,d,n</sup>		
		989.9 ± 92.8 <sup>a,c</sup>		
Codeine (5284371)	-34.2624; 299.37	---	27	Opioid, UGT2B7 substrate
Combretastatin A4 (5351344)	12.5753; 316.353	44.8 ± 3.54 <sup>b,c</sup>	28	Stilbene, plant & UGT1A6 substrate
Daidzein (5281708)	57.7173; 254.241	ND Minimal <sup>a,e</sup>	22 29	Isoflavone, plant substrate
Daphnetin (5280569)	48.3861; 178.143	74.4 ± 4.1 <sup>a,c</sup> 74.4 ± 8.8 <sup>a,c</sup>	30	Coumarin, plant & UGT1A6 substrate
Delphinidin (128853)	42.8066; 303.246	Unknown	31	Anthocyanin, plant substrate & possible poor UGT substrate
Diosmetin (5281612)	53.2596; 300.266	3.02 ± 0.59 <sup>a,c</sup>	32	Flavone, plant substrate & UGT1A6 substrate
Dopamine (681)	58.8765; 153.181	Minimal (rate: ~0.4 pmol/min/mg)	33	Poor UGT1A6 substrate, other UGT substrate
Emodin (3220)	54.8205; 270.24	ND	21	Quinone, plant & other UGT substrate
Endoxifen (10090750)	15.4125; 373.496	ND	9	Tamoxifen metabolite, other UGT substrate
Entacapone (5281081)	47.0507; 305.29	ND	34	Phenolic drug, other UGT substrate
Estradiol (5757)	-8.44673; 272.388	ND	21	Non-metabolized control, other UGT substrate
Ezetimibe (150311)	48.6851; 409.433	ND	35	Phenolic drug, other UGT substrate
Fenretinide (5288209)	-13.6979; 391.555	422 ± 46 <sup>a,c</sup>	36	Phenolic drug, UGT1A6 substrate
Formononetin (5280378)	43.1571; 268.268	ND	22	Isoflavone, plant substrate
Galangin (5281616)	60.0664; 270.24	ND	21	Flavonol, plant substrate & poor UGT1A6 substrate
		Minimal	37	
		Minimal	20	
Genistein (5280961)	57.9287; 270.24	Minimal	22	Isoflavone, plant substrate & poor UGT1A6 substrate
		Minimal (rate: 0.05 nmol/min/mg)	19	
		220 <sup>a,e</sup>	29	

Glycitein (5317750)	52.3694; 284.267	Unknown	29	Isoflavone, plant substrate, possible substrate
Hesperetin (72281)	51.0055; 302.282	Minimal (rate: 0.018 nmol/min/mg)	38	Flavanone, plant substrate & other UGT substrate
Irinotecan (60838)	-28.3631; 586.689	ND	39,40	Phenolic drug, non-metabolized control
Kaempferol (5280863)	72.648; 286.239	Minimal Minimal	41 20	Flavonol, plant substrate
Morphine (5288826)	-8.70848; 285.343	ND	21	Opioid, other UGT substrate
Mycophenolic acid (446541)	13.8351; 320.341	Low activity	42	Phenolic drug, other UGT substrate
Naringenin (932)	49.4201; 272.256	Unknown	43	Falavanone, plant substrate & other UGT substrate
Norepinephrine (439260)	58.9037; 169.18	Unknown		Similar structure to serotonin/dopamine
Oleandomycin (5284598)	-5.40868; 687.868	Unknown		Bacterial substrate
Phenylephrine (6041)	22.9368; 167.208	Unknown	44	Phenolic drug, UGT substrate
Piceatannol (667639)	52.4984; 244.246	Minimal <sup>c</sup>	45	Stilbene, other UGT substrate, very poor UGT1A6 substrate
Prunetin (5281804)	61.2897; 284.267	Minimal	22	Isoflavone, plant substrate
Quercetin (5280343)	73.3885; 302.238	ND 3% conversion	21 46	Flavonol, plant substrate
Raloxifene (5035)	31.8046; 473.587	ND	47	Phenolic drug, non-metabolized control
Scopoletin (5280460)	40.7312; 192.17	194 ± 6.42 <sup>a,c</sup>	3	Scopoletin, UGT1A6 substrate
Serotonin (5202)	26.9016; 176.21	8800 ± 300 <sup>a,k</sup>		
		5900 ± 200 <sup>a,e</sup>		
		6500 ± 900 <sup>a,h</sup>		
		4900 ± 3300 <sup>a,i</sup>		
		12400 ± 2000 <sup>a,j</sup>		
		5000 ± 400 <sup>a,c</sup>		
		6700 ± 200 <sup>a,k</sup>	48	
		6800 ± 400 <sup>a,k</sup>		
		5200 ± 300 <sup>a,k</sup>		UGT1A6 substrate
		8800 ± 300 <sup>a,k</sup>		
SN38 (104842)	-15.0766;	5700 ± 1300 <sup>a,k</sup>		
		6100 ± 800 <sup>a,k</sup>		
		6200 ± 500 <sup>a,k</sup>		
		5400 ± 200 <sup>a,k</sup>		
		7000 ± 300 <sup>a,k,l</sup>	49	
		2840 ± 1940 <sup>a,c</sup>	50	
		9800 ± 500 <sup>a,d</sup>		
		9900 ± 500 <sup>a,d,o</sup>	12	
SN38 (104842)	-15.0766;	97.2 ± 7.9 <sup>a,c</sup>	40	Phenolic drug, UGT1A6 substrate

	392.411	11.6 ± 5.2 <sup>a,d</sup>	39	
Tamoxifen (2733526)	12.3199; 371.524	---		Phenolic drug, non-metabolized control
Testosterone (6013)	-25.8591; 288.431	ND <sup>c</sup>	51	Non-metabolized control, other UGT substrate
trans-Resveratrol (445154)	48.8684; 228.247	Minimal	52	Stilbene, other UGT substrate
Warfarin (54678486)	48.5637; 308.333	ND	10	Coumarin, non-metabolized control
Xanthohumol (639665)	32.1405; 354.402	3% conversion	53	Chalcone, plant substrate & other UGT substrate

ND: not detected, <sup>a</sup> K<sub>m</sub>, <sup>b</sup> S<sub>50</sub>, <sup>c</sup> recombinant protein produced in insect cells infected with baculovirus, <sup>d</sup> recombinant protein produced in HEK293 cells, <sup>e</sup> recombinant protein produced in lymphoblasts, <sup>f</sup> recombinant protein produced in a *Pichia pastoris* yeast expression system, <sup>g</sup> recombinant protein produced in V79 cells, <sup>h</sup> human kidney microsomes, <sup>i</sup> human lung microsomes, <sup>j</sup> human intestinal microsomes, <sup>k</sup> human liver microsomes, <sup>l</sup>\*2 allozyme, <sup>m</sup>\*3 allozyme, <sup>n</sup>\*4 allozyme, <sup>o</sup>i1+i2 splice isoforms, <sup>p</sup> 0.1% BSA. All recombinants are assumed to be the \*1 allozyme unless otherwise indicated.

**Table S7.** Correlation of ligand properties with the -CDOCKER Energy Score

Ligand property	All docked compounds (55)		UGT1A6 substrates (27) <sup>a</sup>		UGT1A6 substrates (13) <sup>b</sup>	
	Correlation (R <sup>2</sup> )	Slope	Correlation (R <sup>2</sup> )	Slope	Correlation (R <sup>2</sup> )	Slope
Molecular weight	0.1165*	-1.620 ± 0.6127	0.04786	-0.6719 ± 0.5994	0.2836	-2.064 ± 0.9892
Molecular volume	0.1955**	-1.787 ± 0.4979	0.1708*	-1.080 ± 0.4758	0.399*	-2.158 ± 0.7988
Number rotatable bonds	0.05447	-0.02733 ± 0.01564	0.2409**	-0.03791 ± 0.01346	0.2728	-0.04488 ± 0.02210
Number H acceptors	0.005818	0.006280 ± 0.01128	0.1629*	0.02745 ± 0.01244	0.06638	0.01720 ± 0.01944
Number H donors	0.01593	-0.006573 ± 0.007096	0.0289	-0.006331 ± 0.007340	0.09776	-0.01277 ± 0.01170
Number total atoms	0.2180***	-0.3261 ± 0.08484	0.2696**	-0.2347 ± 0.07726	0.4658*	-0.4146 ± 0.1339
Number polar atoms <sup>c</sup>	0.001236	-0.003518 ± 0.01373	0.05134	0.01367 ± 0.01176	0.00046	-0.001404 ± 0.01974

<sup>a</sup> Compounds that have some degree of detectable metabolism by UGT1A6; <sup>b</sup> Only those UGT1A6 substrates that have known Km values; <sup>c</sup> Number of oxygen and nitrogen atoms present in the compound; Slope is significantly non-zero: \* p <0.05, \*\* p < 0.01, \*\*\* p<0.001.


**Table S8.** Crystal structures used for definition of co-substrate and substrate docking spheres

Organism (PDB)	Enzyme	Bound co-substrate	Bound substrate	Catalytic His <sup>a</sup>	OH <sup>b</sup>	Nε2:OH (Å) <sup>c</sup>	C1':OH (Å) <sup>d</sup>
<i>Medicago truncatula</i> (2ACW)	Triterpene / Flavonoid GT	UDPG	---	H22	---	---	---
<i>Vitis vinifera</i> (2C1Z)	Flavonoid GT	U2F	Kaempferol	H20	3-OH 7-OH	2.696 9.394	4.263 9.028
<i>Vitis vinifera</i> (2C9Z)	Flavonoid GT	UDP*	Quercetin	H20	3'-OH 4'-OH 3-OH 7-OH	8.555 7.921 3.387 10.31	---
<i>Arabidopsis thaliana</i> (2VCE)	Hydroquinone GT	U2F	2,4,5-trichlorophenol	H19	1-OH	2.324	3.779
<i>Actinoplanes teichomyceticus / Amycolatopsis orientalis</i> (3H4I)	Chimeric GT	U2F	---	D13 <sup>e</sup>	---	---	---
<i>Medicago truncatula</i> (3HBF)	Flavonoid GT	UDP*	Cannabiscetin	H26	3'-OH 3-OH 7-OH	5.448 4.914 12.201	---
<i>Clitoria ternatea</i> (4REL)	Anthocyanidin GT	---	Kaempferol	H17	3-OH 7-OH	2.492 9.515	---
<i>Clitoria ternatea</i> (4REM)	Anthocyanidin GT	---	Delphinidin	H17	3-OH 7-OH	2.51 9.493	---
<i>Saccharomyces cerevisiae</i> (5GL5)	Sterol 3-beta-GT	UDPG	---	D752 <sup>e</sup>	---	---	---
<i>Arabidopsis thaliana</i> (5U6M)	UGT74F2	UDP*	Salicylic acid	H18	2-OH	5.32	---

<sup>a</sup> Position of the catalytic His residue numbered according to the PDB; <sup>b</sup> Position of the commonly glucuronidated OH of the substrate; <sup>c</sup> Distance between the Nε2 of the catalytic His residue and the substrate OH; <sup>d</sup> Distance between the C1' of UDPGA and the substrate OH group to be glucuronidated; <sup>e</sup> These GTs do not have a His residue at this position, instead having an Asp residue \*These bound co-substrates were not used in defining the co-substrate docking sphere.

**Table S9.** Comparison of substrate binding residues between UGT1A6 docked compounds and crystal structures

Compound	Atom	Crystal structure residue	UGT1A6 equivalent	UGT1A6 interacting residue
Quercetin (PDB: 2C9Z)	3'-OH	H <sub>2</sub> O H150 S146 H150 Q188	H180 S177 H180 loop*	K228
	4'-OH			R172
	B ring	F121	A152	
	3-OH	H20	H38	
	4-OH	S18 H20 H <sub>2</sub> O Q84	G36 H38	
	7-OH		N115	H180 R184
Kaempferol (PDBs: 2C1Z   4REL)		S146 Q188 H150	S177 loop* H180	
	4'-OH			K228
	B ring	H2O H2O F12 L82 F121 V274	Q34 I118 A152 V310*	
	3-OH	H20	H17	H38
	4-OH	S18 H2O N137 N84	G36 R172 N115 D181	R172
	7-OH	H <sub>2</sub> O H <sub>2</sub> O H <sub>2</sub> O	loop*	H180 R184
		L196	loop*	
	A ring	F200	K228	
	C ring	F200	K228	
2,4,5-Trichlorophenol (PDB: 2VCE)	1-OH	H19 U2F H <sub>2</sub> O	H38	K228



2-Cl	H19	H38
2-Cl	I86	I119
	W315	loop*
	H <sub>2</sub> O	
4-Cl	F119	A152
	L183	loop*
	P185	loop*
	A387	F393
5-Cl	L118	P151
	V144	S177
	F148	H180
	L183	loop*
		L225
ring	F119	A152
		L225
	A387	F393
		F393

\*UGT1A6 model and plant GT crystal structures aligned poorly in these regions. Water interactions are shown in blue, classical hydrogen bonds in dark green, non-classical hydrogen bonds in pale green, electrostatic interactions are shown in orange, π-π stacking interactions in dark pink π-alkyl interactions in light pink, and π-σ interactions in purple.

**Table S10.** Interactions with selected bound substrates following *in silico* mutagenesis

Mutation	Rank	Substrate	RMSD from WT (Å)	-CDOCKER score (kcal mol <sup>-1</sup> )	-OH <sup>a</sup>	C1':OH (Å) <sup>b</sup>	Nε2:OH (Å) <sup>c</sup>	Interactions <sup>d</sup>
Wild Type	1	Quercetin	---	73.3885	3'-OH	8.34	6.628	
					4'-OH	9.412	9.106	R172/R172, H180,
					3-OH	7.513	5.046	R184/R184, K228
					7-OH	11.743	12.362	
	2	Kaempferol	---	72.648	3-OH	7.455	4.588	R172, H180, R184, K228
					7-OH	11.486	12.003	
	3	Apigenin	---	64.9334	7-OH	11.056	11.184	R172, H180, R184/R184, K228
					4'-OH	11.443	10.525	N115, R184/R184, K228/K228, UDPGA/UDPGA
	4	Prunetin	---	61.2897	5-OH	10.768	10.748	
					3-OH	9.677	7.249	R184/R184, K228, UDPGA
	5	Galangin	---	60.0664	7-OH	11.345	10.577	
	6	Norepinephrine	---	58.9037	5-OH	7.098	6.977	S308, K228, F393, UDPGA
	7	Dopamine	---	58.8765	6-OH	9.33	9.07	
	8	Genistein	---	57.9287	5-OH	6.996	6.692	R172, K228, F393/F393, UDPGA
	32	4-Nitrophenol	---	36.5691	6-OH	9.259	8.861	
	37	Serotonin	---	26.9016	7-OH	11.859	12.213	R172, H180, R184, K228
	39	Acetaminophen	---	22.298	1-OH	9.303	8.691	L225, R184/R184, K228
					5-OH	9.332	9.054	F393, K228, UDPGA/UDPGA <sup>e</sup>
					1-OH	9.535	9.116	R172, K228, UDPGA
H38A	1	Kaempferol	0.1366	71.2639	3-OH	7.439	---	R172, H180, R184, K228
					7-OH	11.531	---	
					3'-OH	10.642	---	
	2	Quercetin	7.3884	70.1748	4'-OH	11.381	---	N115, R172, R184, L225, K228, UDPGA
					3-OH	7.423	---	
D150A	3	Apigenin	0.1222	64.9835	7-OH	9.886	---	
	4	Prunetin	0.1213	61.228	7-OH	11.08	---	R172, H180, R184, K228
					4'-OH	11.407	---	N115, R184, K228/K228, UDPGA/UDPGA
	5	Galangin	5.7322	60.9539	5-OH	10.802	---	
					3-OH	11.342	---	R184, L225, K228/K228
					7-OH	9.211	---	
	1	Quercetin	1.4719	80.8552	3'-OH	8.44	9.083	
					4'-OH	9.182	8.015	R172, H180, R184, K228
					3-OH	7.475	4.497	
					7-OH	11.415	11.896	
	2	Kaempferol	0.7442	72.1385	3-OH	7.538	5.02	R172, H180, R184, K228
					7-OH	11.712	12.304	
	3	Apigenin	0.3409	65.5696	7-OH	11.188	11.491	R172, H180, R184, K228
					3-OH	11.336	10.738	
	4	Galangin	5.7151	62.4565	7-OH	9.196	8.186	R184, L225, K228
					4'-OH	11.414	10.555	

				5-OH	10.883	10.856	N115, R184, K228/K228, UDPGA/UDPGA	
R172A	1	Quercetin	3.6115	68.8932	3'-OH	8.486	8.63	N115, R184/R184, K228/K228, UDPGA/UDPGA
					4'-OH	9.624	10.956	
					3-OH	9.79	7.252	
					7-OH	11.304	10.668	
	2	Kaempferol	3.6909	65.3047	3-OH	9.756	7.251	N115, R184, K228, UDPGA/UDPGA
H180A	3	Apigenin	6.6146	63.289	7-OH	11.31	10.622	H180, R184/R184, K228, UDPGA
	4	Prunetin	2.3509	62.5783	4'-OH	10.246	10.682	R184/R184, K228/K228/K228, UDPGA
					5-OH	7.459	8.192	H38, P151, F171,
							A172/A172 <sup>f</sup> , G173, K228, F393	
	5	Genistein	4.4617	55.9765	7-OH	9.297	5.787	
T181A	1	Quercetin	2.6225	75.2437	3'-OH	8.933	8.629	Q34, H38, R172/R172, S177, R184, K228
					4'-OH	9.334	7.881	
					3-OH	7.669	3.105	
					7-OH	11.316	10.47	
	2	Kaempferol	0.3141	67.5371	3-OH	7.497	4.423	R172, R184, K228
R184A	3	Apigenin	2.4233	60.8558	7-OH	11.362	11.813	N115, R172/R172, R184, K228
	4	Galangin	5.7445	58.9827	3-OH	11.348	10.726	R184, L225, K228
					7-OH	9.175	8.211	
	5	Prunetin	0.2389	58.6895	4'-OH	11.411	10.539	N115, R184, K228/K228, UDPGA
					5-OH	10.849	10.821	
R184A	1	Quercetin	0.6904	72.4485	3'-OH	9.1456	6.161	R172, H180, R184, K228
					4'-OH	9.122	8.134	
					3-OH	7.337	4.948	
					7-OH	11.717	12.427	
	2	Kaempferol	1.9742	70.7189	3-OH	7.671	3.085	Q34, H38, R172/R172, S177, R184, K228
T181A	3	Apigenin	6.3051	62.139	7-OH	11.467	10.473	Q34, R172, H180, R184, K228
	4	Prunetin	3.0043	61.3194	4'-OH	9.194	7.322	
					5-OH	11.354	10.625	Q34, R184, K228
	5	Galangin	7.1028	61.1947	3-OH	9.388	8.508	
					7-OH	11.61	10.41	A181, R184, K228/L225
R184A	32	4-Nitrophenol	3.8724	41.2233	3-OH	9.207	8.256	R184/R184, L225, K228/K228/K228, UDPGA/UDPGA
	38	Serotonin	2.8545	28.0261	4'-OH	11.322	10.797	K228/K228/K228, UDPGA/UDPGA
	41	Acetaminophen	0.167	24.6834	5-OH	9.459	4.593	F393, UDPGA
					1-OH	9.684	9.048	R172, K228
					3-OH	9.463	4.743	

					7-OH	10.956	8.429	
2	Apigenin	10.0196	62.7969	7-OH	11.212	8.797	K88, S308, K228	
3	Kaempferol	1.0595	58.3778	3-OH	7.269	5.381	R172, H180, K228	
4	Dopamine	1.3487	57.2565	7-OH	11.63	12.91		
5	Norepinephrine	1.4025	55.6979	5-OH	7.016	8.392	Y112, K228, F393, UDPGA/UDPGA	
				6-OH	9.386	9.169		
				5-OH	6.983	6.601	R172, K228, F393, UDPGA/UDPGA	
				6-OH	9.315	8.773		
R184S				3'-OH	9.694	7.018		
	1	Quercetin	9.7158	71.4267	4'-OH	9.479	8.798	H38, K88, R172, K228, UDPGA
				3-OH	4.287	4.749		
				7-OH	10.953	8.426		
	2	Apigenin	10.0219	62.7472	7-OH	11.199	8.747	K88, S308, K228
	3	Kaempferol	0.9558	58.9523	3-OH	7.265	5.311	R172, H180, K228
	4	Dopamine	0.2299	57.7143	7-OH	11.864	12.858	
	5	Norepinephrine	0.4429	56.8494	5-OH	7.07	6.743	K228, F393, UDPGA
				6-OH	7.844	8.881		
				5-OH	7.198	7.538		
	32	4-Nitrophenol	6.0794	34.5556	6-OH	9.683	9.592	R172, K228, UDPGA
	37	Serotonin	0.1457	26.737	1-OH	9.511	9.373	K228, F393, UDPGA
	41	Acetaminophen	0.2466	22.1607	5-OH	9.313	8.992	H38, R172, K228, UDPGA
				6-OH	9.396	8.773		
K228A				3'-OH	10.638	11.426		
	1	Quercetin	7.3353	63.2987	4'-OH	11.355	10.889	N115, R172/R172, R184/R184, UDPGA/UDPGA
				3-OH	7.493	5.13		
				7-OH	9.693	10.643		
	2	Kaempferol	5.9363	62.9417	3-OH	11.203	10.78	R172, H180, R184/R184, T204
F393A	3	Apigenin	2.9312	55.546	7-OH	11.38	14.717	N115, R172, R184, F393, UDPGA
	4	Galangin	3.5476	53.2515	7-OH	11.35	10.787	Q34, H38, R172/R172, R184
	5	Genistein	3.4702	52.1346	3-OH	7.719	3.111	N115, R172, R184/R184, L225, UDPGA/UDPGA
				7-OH	11.364	10.576		
				7-OH	11.336	10.686		
				3'-OH	8.996	10.145		
	1	Quercetin	1.4077	74.2709	4'-OH	9.371	9.012	R172, H180, R184, K228
				3-OH	7.447	4.969		
				7-OH	11.729	12.353		
	2	Kaempferol	7.746	71.9498	3-OH	9.483	8.59	R184, L225, K228, A393, UDPGA
	3	Apigenin	7.759	66.7926	7-OH	8.152	12.596	H180, R184, K228, A393, UDPGA
	4	Galangin	2.1694	65.4804	7-OH	9.233	8.135	Y112, R184, K225, K228, A393
	5	Prunetin	1.5133	64.5641	3-OH	9.291	9.006	N115, R184, L225, K228/K228
				7-OH	11.327	10.646		
				4'-OH	11.367	10.614		
				5-OH	10.318	10.133		

<sup>a</sup> Position of the commonly glucuronidated –OH of the substrate; <sup>b</sup> Distance between the C1' of UDPGA and the substrate OH group to be glucuronidated; <sup>c</sup> Distance between the Nε2 of the catalytic H38 residue of UGT1A6 and the substrate OH; <sup>d</sup> Interactions are coloured according to type with electrostatic interactions shown in orange, classical hydrogen bonds in dark green, non-classical hydrogen bonds in pale green, π–π stacking interactions in dark pink, π-alkyl interactions in light pink, and unfavourable interactions in red; <sup>e</sup> Residues shown multiple times in different colours had multiple different types of interactions with the substrate involving different atoms of the residue and/or substrate; <sup>f</sup> Interactions with the mutated residue shown in italics.

**Table S11.** Docking scores and residue distances of top 5 substrates and 3 well-metabolized substrates docked into Ghemtio *et al* (2014) model

Rank	Name	Glucuronidated <sup>a</sup>	-CDOCKER Energy (kcal mol <sup>-1</sup> )	-OH <sup>b</sup>	C1':OH (Å) <sup>c</sup>	Nε2:OH (Å) <sup>d</sup>	Interactions <sup>e</sup>
1	Quercetin	Minimally	64.4719	3'-OH	6.673	3.75	
				4'-OH	8.08	6.059	G36, F171, G173, G394, D395, U2F
				3-OH	6.639	7.244	
				7-OH	8.368	8.254	
2	Apigenin	Minimally	59.4991	7-OH	6.837	5.73	E111, F171, G173, G394, U2F
3	Kaempferol	Minimally	59.3939	3-OH	6.225	7.187	H180, P219, S234, G394, D395, U2F/U2F
				7-OH	7.697	5.132	
4	Genistein	Minimally	54.2317	7-OH	12.482	11.042	G36, H38, H180, P219, S234, F393, G394, D395, U2F
5	Daidzein	Minimally	52.8188	7-OH	3.114	4.48	G36, H38, H180, P219, S234, U2F
30	4-Nitrophenol	Yes	33.5717	1-OH	6.627	5.507	F171/F171, G173, U2F
36	Acetaminophen	Yes	21.6177	1-OH	3.338	4.337	U2F
37	Serotonin	Yes	19.8037	5-OH	7.844	6.165	G36, H38/H38/H38, A152, R172, U2F

<sup>a</sup> Ability of UGT1A6 to glucuronidate this compound as per table S6. <sup>b</sup> Position of the commonly glucuronidated –OH positions of the substrate; <sup>c</sup> Distance between the C1' of U2F and the substrate OH group to be glucuronidated; <sup>d</sup> Distance between the Nε2 of the catalytic H38 residue of UGT1A6 and the substrate OH; <sup>e</sup> Interactions are coloured as in Table S14.

**Table S12.** Change in structures over the course of molecular dynamics simulations

Time	RMSD (Å)			
	UGT1A6 (main chain)	UDPGA	Quercetin	206L
0 ns	0	0	0	1.712
1 ns	3.44	3.1697	3.1697	3.13
5 ns	3.906	3.7971	3.7971	3.307
10 ns	4.093	4.0673	4.0673	3.712
15 ns	4.345	4.8031	4.8031	3.391
20 ns	5.067	5.1696	5.1696	4.295
25 ns	4.517	5.0822	5.0822	3.548
30 ns	5.277	5.7387	5.7387	4.694
35 ns	5.677	7.2824	7.2824	4.893
40 ns	5.668	6.8596	6.8596	4.259
45 ns	5.930	6.6732	6.6732	4.876
50 ns	5.795	6.895	6.895	4.672


**Table S13.** Change in UDPGA interacting residues over time

Substructure	0 ns	1 ns	5 ns	10 ns	15 ns	20 ns	25 ns	30 ns	35 ns	40 ns	45 ns	50 ns
Glucose	R172 <sup>a</sup>	R172 / R172	R172	R172 / R172	H38 / H38	R172 / R172	H38 / H38	S41	R172 / R172	R172 / R172 / R172	R256 / R256	R172 / R172
	S308	R256	R256	R256	R172 / R172	G373	R172 / R172	R172	R256	11x H <sub>2</sub> O / H <sub>2</sub> O	6x H <sub>2</sub> O	7x H <sub>2</sub> O
	F393	S374	H371	G373	R256	S374	H371	S374 / S374	S308			
	D395	D395 / D395	G373	S374	G373	D395 / D395	G373	7x H <sub>2</sub> O	10x H <sub>2</sub> O			
	Q396	Q396	D395 / D395	D395	S374	4x H <sub>2</sub> O / 2x H <sub>2</sub> O	S374					
		9x H <sub>2</sub> O	7x H <sub>2</sub> O	Q396	D395		D395					
				8x H <sub>2</sub> O	Q396 / Q396		Q396					
					3x H <sub>2</sub> O / H <sub>2</sub> O		6x H <sub>2</sub> O					
$\beta$ -phosphate	R172	S41	2x H <sub>2</sub> O	R172	6x H <sub>2</sub> O	H <sub>2</sub> O	3x H <sub>2</sub> O	S374	H375	S374 / S374	H375	S374 / S374
	G307	R172		R256				H375	G376	H375	G376	G376
	S308	2x H <sub>2</sub> O		3x H <sub>2</sub> O				2x H <sub>2</sub> O	H <sub>2</sub> O	H <sub>2</sub> O	2x H <sub>2</sub> O	2x H <sub>2</sub> O
$\alpha$ -phosphate	S37	S41	3x H <sub>2</sub> O	S41	H371	G307	H371	H371	G307	H371	H371	H371
	R256	R256		R256	3x H <sub>2</sub> O	S308	3x H <sub>2</sub> O	G373	H371	G373	G376 / G376	G373
	G307	H <sub>2</sub> O		2x H <sub>2</sub> O		H371		3x H <sub>2</sub> O	G376	G376	3x H <sub>2</sub> O	G376 / G376
	H371					H <sub>2</sub> O				2x H <sub>2</sub> O		2x H <sub>2</sub> O
	G373											
	H375											
	G376											
Ribose	G307 / G307	G307 / G307	S308	3x H <sub>2</sub> O / H <sub>2</sub> O	G307	2x H <sub>2</sub> O	S308	4x H <sub>2</sub> O	S308	G307	S308	G307
	N356 / N356	4x H <sub>2</sub> O	4x H <sub>2</sub> O		S308		5x H <sub>2</sub> O		8x H <sub>2</sub> O	S308	4x H <sub>2</sub> O / 2x H <sub>2</sub> O	H371
					4x H <sub>2</sub> O				5x H <sub>2</sub> O			6x H <sub>2</sub> O

	L281	Q356	K283	W353	G307	R335	R335	G307	G307	S308	Y336	R335
Pyrimidine ring	R335	3x H <sub>2</sub> O	3x H <sub>2</sub> O	6x H <sub>2</sub> O	R335	Y336	Y336	R335	S308 / S308	Y336	T337	Y336
	W353				T337	T337	T337	6x H <sub>2</sub> O	Y336	T337	4x H <sub>2</sub> O	T337
	L354				6x H <sub>2</sub> O	2x H <sub>2</sub> O	7x H <sub>2</sub> O		T337	2x H <sub>2</sub> O		3x H <sub>2</sub> O
	P355								4x H <sub>2</sub> O			
	Q356											
	N357											
	E379											

<sup>a</sup> Interactions are coloured as in Table S10, with water interactions shown in blue.

**Table S14.** Change in Quercetin interacting residues over time.

Compound	Atom	0 ns	1 ns	5 ns	10 ns	15 ns	20 ns	25 ns	30 ns	35 ns	40 ns	45 ns	50 ns
	Quercetin	3'-OH	A152	2x H <sub>2</sub> O	Y229	H <sub>2</sub> O	Y247	Y247	K228	K228 / K228	K228	K228	3x H <sub>2</sub> O
			H <sub>2</sub> O		H <sub>2</sub> O			H <sub>2</sub> O	K228		H <sub>2</sub> O	K228	
	4'-OH	H38	K228	K228	Y229	H <sub>2</sub> O	Y229	H <sub>2</sub> O	C224	K228 / K228	K228	K228	3x H <sub>2</sub> O
		K228	K228	3x H <sub>2</sub> O	Y229				K228		H <sub>2</sub> O	H <sub>2</sub> O	
	B ring	A152	A152	L225	A152	L225	L225	C224**	L225	L225	L221	L225	L225
					L225						L225		
	A ring	R184	F171	F171	F171	H <sub>2</sub> O*	P154	A152	A152	A152	A152	A152	A152
	C ring	F171	F171	F171	H <sub>2</sub> O*	A152 / A152*	A152	A152	A152	A152	A152	A152	A152
3-OH	R172	A152	R172	A152	R172	H38	R172	A152	H38	A152	H38	A152	H <sub>2</sub> O
					H <sub>2</sub> O	R172							
	4-OH	H <sub>2</sub> O	H <sub>2</sub> O	H <sub>2</sub> O	R172	3x H <sub>2</sub> O	R172	3x H <sub>2</sub> O	2x H <sub>2</sub> O	2x H <sub>2</sub> O	2x H <sub>2</sub> O	A152	H <sub>2</sub> O
					H <sub>2</sub> O								
	5-OH	G173	G173	H <sub>2</sub> O	G394	G394	D395	2x H <sub>2</sub> O	H <sub>2</sub> O / H <sub>2</sub> O	R172	H <sub>2</sub> O	H <sub>2</sub> O	H <sub>2</sub> O
					H <sub>2</sub> O	H <sub>2</sub> O							
7-OH	H180	S177	S177	G394	H180	R172	H180	H180	Y247	2x H <sub>2</sub> O	4x H <sub>2</sub> O	P154	Y247
		F393	G394	H <sub>2</sub> O	H <sub>2</sub> O								
	R184	G394	H <sub>2</sub> O	H <sub>2</sub> O	2x H <sub>2</sub> O	H <sub>2</sub> O	2x H <sub>2</sub> O	H <sub>2</sub> O	Y247	2x H <sub>2</sub> O	4x H <sub>2</sub> O	H <sub>2</sub> O	H <sub>2</sub> O
		H <sub>2</sub> O											

\*π-lone pair interaction, \*\*π-sulfur interaction, other interactions are coloured according to type as in Table S10, with water interactions shown in blue.

**Table S15.** Distances between potential quercetin glucuronidation sites and important enzyme and co-substrate atoms over time.

Measure	Slope	Distance (Å)										
		0 ns	5 ns	10 ns	15 ns	20 ns	25 ns	30 ns	35 ns	40 ns	45 ns	50 ns
3'-OH:Nε2	-0.0005236 ± 1.286e-005	6.628	10.590	10.230	9.845	9.541	10.533	10.599	7.0179	8.156	6.900	8.156
3'-OH: C1'	0.001473 ± 1.395e-005	8.34	15.590	15.413	16.034	14.635	15.452	18.611	21.736	18.421	20.506	21.140
4'-OH:Nε2	0.0004419 ± 1.046e-005	6.451	8.338	8.420	8.699	9.999	8.920	9.050	9.261	9.885	9.445	10.680
4'-OH:C1'	0.001922 ± 1.689e-005	11.732	15.086	15.219	15.845	16.206	14.869	18.766	23.312	19.335	21.978	22.626
3-OH:Nε2	-0.0001180 ± 1.155e-005	5.046	7.906	8.159	4.779	7.180	6.996	6.565	6.479	4.993	5.675	6.695
3-OH:C1'	0.001755 ± 1.489e-005	7.513	10.231	10.508	9.794	10.101	10.550	12.856	17.537	13.382	15.648	16.670
7-OH:Nε2	-0.0005080 ± 1.322e-005	12.362	14.183	12.662	11.119	12.457	11.966	10.599	11.614	10.269	13.112	9.142
7-OH:C1'	0.001642 ± 1.767e-005	11.743	11.079	10.588	13.092	12.616	11.428	14.931	19.549	11.811	17.492	18.535

**Table S16.** Top 10 I-TASSER threading alignments for each set of input conditions

Input	Rank <sup>a</sup>	Algorithm	PDB:Chain	Thread ID (%) <sup>b</sup>	Total ID (%) <sup>c</sup>	Coverage <sup>d</sup>	Z-score <sup>e</sup>
WSNT	1	MUSTER	<a href="#">5gl5:A</a>	18	18	0.78	1.75
	2	FFAS-3D	<a href="#">5gl5:A</a>	17	18	0.78	2.99
	3	SPARKS-X	<a href="#">2iya:A</a>	17	18	0.72	1.74
	4	HHSEARCH2	<a href="#">5gl5:A</a>	18	18	0.78	2.56
	5	HHSEARCH I	<a href="#">5gl5:A</a>	18	18	0.78	2.23
	6	Neff-PPAS	<a href="#">2iyf:B</a>	18	18	0.73	2.46
	7	HHSEARCH	<a href="#">2pq6:A</a>	20	17	0.74	3.22
	8	pGenTHREADER	<a href="#">4m83:A</a>	17	19	0.73	4.39
	9	wdPPAS	<a href="#">5gl5:A</a>	18	18	0.78	1.62
	10	cdPPAS	<a href="#">2iya:A</a>	00	18	0.73	2.83
NSNT	1	MUSTER	<a href="#">5gl5:A</a>	17	20	0.82	1.78
	2	FFAS-3D	<a href="#">2iyf:A</a>	18	19	0.75	3.03
	3	SPARKS-X	<a href="#">2iya:A</a>	18	19	0.74	1.86
	4	HHSEARCH2	<a href="#">5gl5:A</a>	18	20	0.81	2.59
	5	HHSEARCH I	<a href="#">5gl5:A</a>	18	20	0.82	2.20
	6	Neff-PPAS	<a href="#">2iyf:B</a>	18	19	0.76	2.57
	7	HHSEARCH	<a href="#">2pq6:A</a>	20	18	0.79	3.23
	8	pGenTHREADER	<a href="#">2iya:A</a>	18	19	0.76	4.28
	9	wdPPAS	<a href="#">2iyf:B</a>	18	19	0.76	1.66
	10	PROSPECT2	<a href="#">2iyf:A</a>	18	19	0.75	2.93
WSWT	1	USER <sup>f</sup>	<a href="#">2o6l:A</a>	55	17	0.30	10.00
	2	FFAS-3D	<a href="#">2o6l:A</a>	58	16	0.29	2.35
	3	FFAS03	<a href="#">2o6l:A</a>	54	16	0.29	2.95
	4	pGenTHREADER	<a href="#">2o6l:A</a>	59	18	0.30	3.54
	5	HHSEARCH I	<a href="#">2acv:A</a>	16	18	0.75	1.82
	6	HHSEARCH2	<a href="#">2acv:A</a>	16	18	0.75	2.33
	7	SPARKS-X	<a href="#">2acv:A</a>	16	18	0.76	1.30
	8	HHSEARCH	<a href="#">2acv:A</a>	15	18	0.76	2.69
	9	HHSEARCH2	<a href="#">5tme:A</a>	18	18	0.73	2.33
	10	HHSEARCH	<a href="#">5tme:A</a>	18	18	0.73	2.86
NSWT	1	USER	<a href="#">2o6l:A</a>	55	17	0.32	10.00
	2	FFAS-3D	<a href="#">2o6l:A</a>	58	17	0.31	2.35
	3	FFAS03	<a href="#">2o6l:A</a>	53	17	0.30	2.98
	4	pGenTHREADER	<a href="#">2o6l:A</a>	59	19	0.32	3.43
	5	HHSEARCH I	<a href="#">2acv:A</a>	16	19	0.77	1.83
	6	HHSEARCH I	<a href="#">5tme:A</a>	18	19	0.77	1.98
	7	HHSEARCH2	<a href="#">2acv:A</a>	16	19	0.77	2.35
	8	SPARKS-X	<a href="#">2acv:A</a>	18	19	0.79	1.38
	9	HHSEARCH	<a href="#">2acv:A</a>	15	19	0.79	2.76
	10	HHSEARCH2	<a href="#">5tme:A</a>	18	19	0.77	2.42

<sup>a</sup> Top ten threading templates used by I-TASSER, <sup>b</sup> Percent sequence identity of template and query sequence within threading aligned region, <sup>c</sup> percent sequence identity over the entire template and query sequence, <sup>d</sup> coverage of the threading alignment with query (number aligned residues divided by length of query), <sup>e</sup> Normalized Z-score of the threading alignments, alignments with a score >1 indicate a good alignment, <sup>f</sup> user supplied template sequence – UGT2B7 C-terminal end. Structural and sequence alignments are available in the “Supplemental structures” zip file.

**Table S17.** Top 10 identified structural analogues to I-TASSER constructed models

Model	Rank <sup>a</sup>	PDB	Enzyme	TM-score	RMSD <sup>b</sup>	ID <sup>c</sup>	Coverage <sup>d</sup>
WSNT	1	<a href="#">5gl5:A</a>	Sterol 3-beta-glucosyltransferase	0.777	0.9	0.165	0.786
	2	<a href="#">1rrv:A</a>	TDP-vancosaminyltransferase GtfD	0.663	3.09	0.157	0.737
	3	<a href="#">1iir:A</a>	UDP-glucosyltransferase GtfB	0.651	2.48	0.152	0.703
	4	<a href="#">3oth:A</a>	Calicheamicin Glycosyltransferase	0.632	3.47	0.139	0.714
	5	<a href="#">3rsc:A</a>	Calicheamicin Glycosyltransferase	0.629	3.54	0.178	0.716
	6	<a href="#">3h4t:A</a>	Chimeric glycosyltransferase	0.625	3.18	0.159	0.701
	7	<a href="#">2acw:A</a>	Triterpene/Flavonoid Glycosyltransferase	0.624	4.25	0.155	0.733
	8	<a href="#">2iya:A</a>	Oleandomycin Glycosyltransferase	0.622	3.6	0.179	0.707
	9	<a href="#">3wc4:A</a>	anthocyanidin 3-O-glucosyltransferase	0.62	4.41	0.15	0.733
	10	<a href="#">3ia7:A</a>	Calicheamicin Glycosyltransferase	0.618	3.76	0.161	0.724
NSNT	1	<a href="#">5gl5:A</a>	Sterol 3-beta-glucosyltransferase	0.806	1.12	0.181	0.818
	2	<a href="#">1rrv:A</a>	TDP-vancosaminyltransferase GtfD	0.701	2.87	0.155	0.773
	3	<a href="#">1iir:A</a>	UDP-glucosyltransferase GtfB	0.683	2.51	0.147	0.737
	4	<a href="#">3rsc:A</a>	Calicheamicin Glycosyltransferase	0.666	3.37	0.175	0.751
	5	<a href="#">3h4i:A</a>	Chimeric glycosyltransferase	0.659	3.01	0.161	0.731
	6	<a href="#">2iya:A</a>	Oleandomycin Glycosyltransferase	0.658	3.32	0.177	0.743
	7	<a href="#">3oth:A</a>	Calicheamicin Glycosyltransferase	0.656	3.58	0.14	0.745
	8	<a href="#">5tmb:A</a>	Ox70 UDP-glucosyltransferase	0.649	4.31	0.162	0.767
	9	<a href="#">3ia7:A</a>	Calicheamicin Glycosyltransferase	0.648	3.77	0.161	0.759
	10	<a href="#">1pnv:B</a>	TDP-epi-Vancosaminyltransferase GtfA	0.646	3.19	0.14	0.727
WSWT	1	<a href="#">2acw:A</a>	Triterpene/Flavonoid Glycosyltransferase	0.715	2.05	0.16	0.752
	2	<a href="#">2vce:A</a>	Hydroquinone Glucosyltransferase	0.699	2.49	0.157	0.748
	3	<a href="#">3wc4:A</a>	anthocyanidin 3-O-glucosyltransferase	0.694	2.9	0.16	0.763
	4	<a href="#">5tmb:A</a>	Ox70 UDP-glucosyltransferase	0.69	2.76	0.163	0.75
	5	<a href="#">3hbj:A</a>	Flavonoid 3-O-glucosyltransferase	0.689	2.84	0.181	0.757
	6	<a href="#">2c9z:A</a>	Flavonoid 3-O-glucosyltransferase	0.685	2.88	0.162	0.752
	7	<a href="#">5u6m:A</a>	UDP-glycosyltransferase 74F2	0.684	2.57	0.178	0.739
	8	<a href="#">2pq6:A</a>	UDP-glucosyltransferase	0.67	2.81	0.195	0.729
	9	<a href="#">5gl5:A</a>	Sterol 3-beta-glucosyltransferase	0.66	3.6	0.156	0.748
	10	<a href="#">3oth:A</a>	Calicheamicin Glycosyltransferase	0.629	3.5	0.158	0.72
NSWT	1	<a href="#">2acw:A</a>	Triterpene/Flavonoid Glycosyltransferase	0.73	2.28	0.163	0.777
	2	<a href="#">5tmb:A</a>	Ox70 UDP-glucosyltransferase	0.726	2.51	0.167	0.781
	3	<a href="#">2vce:A</a>	Hydroquinone Glucosyltransferase	0.726	2.6	0.158	0.783
	4	<a href="#">5u6m:A</a>	UDP-glycosyltransferase 74F2	0.72	2.44	0.181	0.775
	5	<a href="#">3wc4:A</a>	anthocyanidin 3-O-glucosyltransferase	0.713	2.95	0.162	0.79
	6	<a href="#">3hbj:A</a>	Flavonoid 3-O-glucosyltransferase	0.711	2.91	0.168	0.787
	7	<a href="#">2c9z:A</a>	Flavonoid 3-O-glucosyltransferase	0.71	2.94	0.156	0.785
	8	<a href="#">2pq6:A</a>	UDP-glucosyltransferase	0.697	2.77	0.193	0.761
	9	<a href="#">5gl5:A</a>	Sterol 3-beta-glucosyltransferase	0.682	3.83	0.15	0.785
	10	<a href="#">2iya:A</a>	Oleandomycin Glycosyltransferase	0.65	3.55	0.192	0.745

<sup>a</sup>Rank is based on TM-score; <sup>b</sup>RMSD is the RMSD in Å between residues that are structurally aligned by TM-align; <sup>c</sup>the percent sequence identity in the structurally aligned region; <sup>d</sup>the number of structurally aligned residues divided by length of the query protein.

**Table S18.** Glycosyltransferase crystal structures available in the RCSB database

PDB	Kingdom	Organism	Enzyme	Gene	Uniprot
1F0K	Bacteria	<i>Escherichia coli</i> (K12)	UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase	murG	P17443
1IIR	Bacteria	<i>Amycolatopsis orientalis</i>	UDP-glucosyltransferase GtfB	GtfB	P96559
1NLM	Bacteria	<i>Escherichia coli</i> (K12)	UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase	murG	P17443
1PN3	Bacteria	<i>Amycolatopsis orientalis</i>	TDP-epi-Vancosaminyltransferase GtfA	GtfA	P96558
1PNV	Bacteria	<i>Amycolatopsis orientalis</i>	TDP-epi-Vancosaminyltransferase GtfA	GtfA	P96558
1RRV	Bacteria	<i>Amycolatopsis orientalis</i>	TDP-vancosaminyltransferase GtfD	GtfD	Q9AFC7
2ACV	Plantae	<i>Medicago truncatula</i>	Triterpene/Flavonoid Glycosyltransferase	UGT71G1	Q5IFH7
2ACW	Plantae	<i>Medicago truncatula</i>	Triterpene/Flavonoid Glycosyltransferase	UGT71G1	Q5IFH7
2C1X	Plantae	<i>Vitis vinifera</i>	Flavonoid 3-O-glucosyltransferase	UGT71G1	P51094
2C1Z	Plantae	<i>Vitis vinifera</i>	Flavonoid 3-O-glucosyltransferase	UGT71G1	P51094
2C9Z	Plantae	<i>Vitis vinifera</i>	Flavonoid 3-O-glucosyltransferase	UGT71G1	P51094
2HY7	Bacteria	<i>Xanthomonas campestris</i> pv. Campestris	beta-1,2-glucuronosyltransferase	gumK	Q8GCH2
2IYA	Bacteria	<i>Streptomyces antibioticus</i>	Oleandomycin Glycosyltransferase	OleI	Q3HTL7
2O6L	Animalia	<i>Homo sapiens</i>	UDP-Glucuronosyltransferase 2B7	UGT2B7	P16662
2P6P	Bacteria	<i>Streptomyces fradiae</i>	dTDP-D-Olivose-transferase UrdGT2	UrdGT2	Q9RPA7
2PQ6	Plantae	<i>Medicago truncatula</i>	UDP-glucosyltransferase	UGT85H2	A6XNC5
2Q6V	Bacteria	<i>Xanthomonas campestris</i> pv. Campestris	beta-1,2-glucuronosyltransferase	gumK	Q8GCH2
2VCE	Plantae	<i>Arabidopsis thaliana</i>	Hydroquinone Glucosyltransferase	UGT72B1	Q9M156
2VCH	Plantae	<i>Arabidopsis thaliana</i>	Hydroquinone Glucosyltransferase	UGT72B1	Q9M156
2VG8	Plantae	<i>Arabidopsis thaliana</i>	Hydroquinone Glucosyltransferase	UGT72B1	Q9M156
3CUY	Bacteria	<i>Xanthomonas campestris</i> pv. Campestris	beta-1,2-glucuronosyltransferase	gumK	Q8GCH2
3CV3	Bacteria	<i>Xanthomonas campestris</i> pv. Campestris	beta-1,2-glucuronosyltransferase	gumK	Q8GCH2
3D0R	Bacteria	<i>Micromonospora echinospora</i>	Calicheamicin Glycosyltransferase	CalG3	Q8KND7
3H4I	Bacteria	<i>Actinoplanes teichomyceticus</i> , <i>Amycolatopsis orientalis</i>	Chimeric glycosyltransferase	tcp8, gtfA	Q6ZZJ7
3H4T	Bacteria	<i>Actinoplanes teichomyceticus</i> , <i>Amycolatopsis orientalis</i>	Chimeric glycosyltransferases	tcp8, gtfA	P96558
3HBF	Plantae	<i>Medicago truncatula</i>	Flavonoid 3-O-glucosyltransferase	UGT78G1	A6XNC6
3HBJ	Plantae	<i>Medicago truncatula</i>	Flavonoid 3-O-glucosyltransferase	UGT78G1	A6XNC6
3IA7	Bacteria	<i>Micromonospora echinospora</i>	Calicheamicin Glycosyltransferase	CalG4	Q8KNC3
3OTG	Bacteria	<i>Micromonospora echinospora</i>	Calicheamicin Glycosyltransferase	CalG1	Q8KNF2
3OTH	Bacteria	<i>Micromonospora echinospora</i>	Calicheamicin Glycosyltransferase	CalG1	Q8KNF2
3RSC	Bacteria	<i>Micromonospora echinospora</i>	Calicheamicin Glycosyltransferase	CalG2	Q8KNE0

3S2U	Bacteria	<i>Pseudomonas aeruginosa</i>	UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase	murG	Q9HW01
3WC4	Plantae	<i>Clitoria ternatea</i>	anthocyanidin 3-O-glucosyltransferase	Ct3GT-A	A4F1R4
4PQG	Bacteria	<i>Streptococcus pneumoniae</i> (strain ATCC BAA-334 / TIGR4)	Glycosyltransferase GtfA	gtfA	A0A0H2URG7
4REL	Plantae	<i>Clitoria ternatea</i>	anthocyanidin 3-O-glucosyltransferase	Ct3GT-A	A4F1R4
4REM	Plantae	<i>Clitoria ternatea</i>	anthocyanidin 3-O-glucosyltransferase	Ct3GT-A	A4F1R4
4REN	Plantae	<i>Clitoria ternatea</i>	anthocyanidin 3-O-glucosyltransferase	Ct3GT-A	A4F1R4
4WHM	Plantae	<i>Clitoria ternatea</i>	anthocyanidin 3-O-glucosyltransferase	Ct3GT-A	A4F1R4
4WYI	Plantae	<i>Arabidopsis thaliana</i>	Monogalactosyldiacylglycerol synthase 1	MGD1	O81770
4X1T	Plantae	<i>Arabidopsis thaliana</i>	Monogalactosyldiacylglycerol synthase 1	MGD1	O81770
5E9T	Bacteria	<i>Streptococcus gordonii</i>	Glycosyltransferase GtfA/GtfB complex	GtfA/GtfB	Q9AET5 Q79T00
5E9U	Bacteria	<i>Streptococcus gordonii</i>	Glycosyltransferase GtfA/GtfB complex	GtfA/GtfB	Q9AET5 Q79T00
5GL5	Fungi	<i>Saccharomyces cerevisiae</i> (strain ATCC 204508 / S288c)	Sterol 3-beta-glucosyltransferase	ugt51	Q06321
5NLM	Plantae	<i>Polygonum tinctorium</i>	UDP-glucosyltransferase	PtUGT1	A0A2R2JFJ4
5TMB	Plantae	<i>Oryza sativa subsp. japonica</i>	Os70 UDP-glucosyltransferase	UGT70	Q7XT97
5TMD	Plantae	<i>Oryza sativa subsp. japonica</i>	UDP-glycosyltransferase 79	UGT79	Q7XT97
5TME	Plantae	<i>Oryza sativa subsp. Japonica</i>	UDP-glycosyltransferase 79	UGT79	Q7XT97
5U6M	Plantae	<i>Arabidopsis thaliana</i>	UDP-glycosyltransferase 74F2	UGT74F2	O22822
5U6N	Plantae	<i>Arabidopsis thaliana</i>	UDP-glycosyltransferase 74F2	UGT74F2	O22822
5U6S	Plantae	<i>Arabidopsis thaliana</i>	UDP-glycosyltransferase 74F2	UGT74F2	O22822
5V2J	Plantae	<i>Arabidopsis thaliana</i>	UDP-glycosyltransferase 74F2	UGT74F2	O22822
5V2K	Plantae	<i>Arabidopsis thaliana</i>	UDP-glycosyltransferase 74F2	UGT74F2	O22822
5XVM	Fungi	<i>Saccharomyces cerevisiae</i> (strain ATCC 204508 / S288c)	Sterol 3-beta-glucosyltransferase	ugt51	Q06321
6BK2	Plantae	<i>Oryza sativa subsp. japonica</i>	UDP-glycosyltransferase 79	UGT79	Q7XT97
6BK0	Plantae	<i>Oryza sativa subsp. japonica</i>	UDP-glycosyltransferase 79	UGT79	Q7XT97
6BK3	Plantae	<i>Oryza sativa subsp. japonica</i>	UDP-glycosyltransferase 79	UGT79	Q7XT97
6BK1	Plantae	<i>Oryza sativa subsp. japonica</i>	UDP-glycosyltransferase 79	UGT79	Q7XT97
6IJ7	Plantae	<i>Arabidopsis thaliana</i>	Flavonol 7-O-rhamnosyltransferase	UGT89C1	Q9LNE6
6IJA	Plantae	<i>Arabidopsis thaliana</i>	Flavonol 7-O-rhamnosyltransferase	UGT89C1	Q9LNE6
6IJD	Plantae	<i>Arabidopsis thaliana</i>	Flavonol 7-O-rhamnosyltransferase	UGT89C1	Q9LNE6
6IPB	Animalia	<i>Homo sapiens</i>	UDP-Glucuronosyltransferase 2B15	UGT2B15	P54855
6O86	Plantae	<i>Stevia rebaudiana</i>	UDP-glycosyltransferase 76G1	UGT76G1	Q6VAB4
6O87	Plantae	<i>Stevia rebaudiana</i>	UDP-glycosyltransferase 76G1	UGT76G1	Q6VAB4
6O88	Plantae	<i>Stevia rebaudiana</i>	UDP-glycosyltransferase 76G1	UGT76G1	Q6VAB4

**Table S19.** Mutant UGT1A6 structures produced for investigating effects of specific residues on compound binding

Importance	Original amino acid	Position	Changed amino acid	Purpose
Co-substrate binding	Ser	37	Ala	Examine co-substrate binding
Catalytic	His	38	Ala	Examine co-substrate and substrate binding
Catalytic	Asp	150	Ala	Examine co-substrate and substrate binding
Co-substrate and substrate binding	Arg	172	Ala	Examine co-substrate and substrate binding
Substrate binding	His	180	Ala	Examine substrate binding
Polymorphism	Thr	181	Ala	Examine substrate binding
Substrate binding	Arg	184	Ala	Examine substrate binding
Polymorphism	Arg	184	Ser	Examine substrate binding
Substrate binding	Lys	228	Ala	Examine substrate binding
Co-substrate binding	Ser	308	Ala	Examine co-substrate binding
Co-substrate binding	Trp	353	Ala	Examine co-substrate binding
Co-substrate binding	Leu	354	Ala	Examine co-substrate binding
Co-substrate binding	His	375	Ala	Examine co-substrate binding
Co-substrate binding	Gly	376	Ala	Examine co-substrate binding
Co-substrate and substrate binding	Phe	393	Ala	Examine co-substrate and substrate binding

## REFERENCES – SUPPORTING INFORMATION

- (1) Ghemtio, L.; Soikkeli, A.; Yliperttula, M.; Hirvonen, J.; Finel, M.; Xhaard, H. SVM Classification and CoMSIA Modeling of UGT1A6 Interacting Molecules. *J. Chem. Inf. Model.* **2014**, *54* (4), 1011–1026. <https://doi.org/10.1021/ci400577a>.
- (2) Vaidyanathan, J. B.; Walle, T. Glucuronidation and Sulfation of the Tea Flavonoid (–)-Epicatechin by the Human and Rat Enzymes. *Drug Metab. Dispos.* **2002**, *30* (8), 897–903. <https://doi.org/10.1124/dmd.30.8.897>.
- (3) Luukkanen, L.; Taskinen, J.; Kurkela, M.; Kostiainen, R.; Hirvonen, J.; Finel, M. Kinetic Characterization of the 1a Subfamily of Recombinant Human Udp-Glucuronosyltransferases. *Drug Metab. Dispos.* **2005**, *33* (7), 1017–1026. <https://doi.org/10.1124/dmd.105.004093>.
- (4) Soars, M. G.; Ring, B. J.; Wrighton, S. A. The Effect of Incubation Conditions on the Enzyme Kinetics of Udp-Glucuronosyltransferases. *Drug Metab. Dispos.* **2003**, *31* (6), 762–767. <https://doi.org/10.1124/dmd.31.6.762>.
- (5) Liu, Y.; She, M.; Wu, Z.; Dai, R. The Inhibition Study of Human UDP-Glucuronosyltransferases with Cytochrome P450 Selective Substrates and Inhibitors. *J. Enzyme Inhib. Med. Chem.* **2011**, *26* (3), 386–393. <https://doi.org/10.3109/14756366.2010.518965>.
- (6) Uchaipichat, V.; Mackenzie, P. I.; Guo, X.-H.; Gardner-Stephen, D.; Galetin, A.; Houston, J. B.; Miners, J. O. Human Udp-Glucuronosyltransferases: Isoform Selectivity and Kinetics of 4-Methylumbellifereone and 1-Naphthol Glucuronidation, Effects of Organic Solvents, and Inhibition by Diclofenac and Probenecid. *Drug Metab. Dispos. Biol. Fate Chem.* **2004**, *32* (4), 413–423. <https://doi.org/10.1124/dmd.32.4.413>.
- (7) Manevski, N.; Troberg, J.; Svaluto-Moreolo, P.; Dziedzic, K.; Yli-Kauhaluoma, J.; Finel, M. Albumin Stimulates the Activity of the Human UDP-Glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the Effects Are Enzyme and Substrate Dependent. *PLOS ONE* **2013**, *8* (1), e54767. <https://doi.org/10.1371/journal.pone.0054767>.
- (8) Brazier-Hicks, M.; Edwards, R. Functional Importance of the Family 1 Glucosyltransferase UGT72B1 in the Metabolism of Xenobiotics in *Arabidopsis Thaliana*. *Plant J. Cell Mol. Biol.* **2005**, *42* (4), 556–566. <https://doi.org/10.1111/j.1365-313X.2005.02398.x>.
- (9) Sun, D.; Sharma, A. K.; Dellinger, R. W.; Blevins-Primeau, A. S.; Balliet, R. M.; Chen, G.; Boyiri, T.; Amin, S.; Lazarus, P. Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases. *Drug Metab. Dispos.* **2007**, *35* (11), 2006–2014. <https://doi.org/10.1124/dmd.107.017145>.
- (10) Zielinska, A.; Lichti, C. F.; Bratton, S.; Mitchell, N. C.; Gallus-Zawada, A.; Le, V.-H.; Finel, M.; Miller, G. P.; Radominska-Pandya, A.; Moran, J. H. Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases. *J. Pharmacol. Exp. Ther.* **2008**, *324* (1), 139–148. <https://doi.org/10.1124/jpet.107.129858>.
- (11) Li, D.; Fournel-Gigleux, S.; Barré, L.; Mulliert, G.; Netter, P.; Magdalou, J.; Ouzzine, M. Identification of Aspartic Acid and Histidine Residues Mediating the Reaction Mechanism and the Substrate Specificity of the Human UDP-Glucuronosyltransferases 1A. *J. Biol. Chem.* **2007**, *282* (50), 36514–36524. <https://doi.org/10.1074/jbc.M703107200>.
- (12) Benoit-Biancamano, M.-O.; Connelly, J.; Villeneuve, L.; Caron, P.; Guillemette, C. Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants. *Drug Metab. Dispos.* **2009**, *37* (2), 322–329. <https://doi.org/10.1124/dmd.108.023101>.
- (13) Nagar, S.; Zalatoris, J. J.; Blanchard, R. L. Human UGT1A6 Pharmacogenetics: Identification of a Novel SNP, Characterization of Allele Frequencies and Functional Analysis of Recombinant Allozymes in Human Liver Tissue and in Cultured Cells. *Pharmacogenetics* **2004**, *14* (8), 487–499.
- (14) Ethell, B. T.; Ekins, S.; Wang, J.; Burchell, B. Quantitative Structure Activity Relationships for the Glucuronidation of Simple Phenols by Expressed Human UGT1A6 and UGT1A9. *Drug Metab. Dispos.* **2002**, *30* (6), 734–738. <https://doi.org/10.1124/dmd.30.6.734>.
- (15) Miners, J. O.; Bowalgaha, K.; Elliot, D. J.; Baranczewski, P.; Knights, K. M. Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation. *Drug Metab. Dispos.* **2011**, *39* (4), 644–652. <https://doi.org/10.1124/dmd.110.037036>.
- (16) Court, M. H.; Duan, S. X.; Moltke, L. L. von; Greenblatt, D. J.; Patten, C. J.; Miners, J. O.; Mackenzie, P. I. Interindividual Variability in Acetaminophen Glucuronidation by Human Liver Microsomes: Identification of

- Relevant Acetaminophen UDP-Glucuronosyltransferase Isoforms. *J. Pharmacol. Exp. Ther.* **2001**, *299* (3), 998–1006.
- (17) Mutlib, A. E.; Goosen, T. C.; Bauman, J. N.; Williams, J. A.; Kulkarni, S.; Kostrubsky, S. Kinetics of Acetaminophen Glucuronidation by UDP-Glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential Implications in Acetaminophen-Induced Hepatotoxicity. *Chem. Res. Toxicol.* **2006**, *19* (5), 701–709. <https://doi.org/10.1021/tx050317i>.
- (18) Hagenauer, B.; Salamon, A.; Thalhammer, T.; Kunert, O.; Haslinger, E.; Klingler, P.; Senderowicz, A. M.; Sausville, E. A.; Jäger, W. In Vitro Glucuronidation of the Cyclin-Dependent Kinase Inhibitor Flavopiridol by Rat and Human Liver Microsomes: Involvement of UDP-Glucuronosyltransferases 1A1 and 1A9. *Drug Metab. Dispos.* **2001**, *29* (4), 407–414.
- (19) Liu, X.; Tam, V. H.; Hu, M. Disposition of Flavonoids via Enteric Recycling: Determination of the UDP-Glucuronosyltransferase Isoforms Responsible for the Metabolism of Flavonoids in Intact Caco-2 TC7 Cells Using SiRNA. *Mol. Pharm.* **2007**, *4* (6), 873–882. <https://doi.org/10.1021/mp0601190>.
- (20) Singh, R.; Wu, B.; Tang, L.; Hu, M. Uridine Diphosphate Glucuronosyltransferase Isoform-Dependent Regiospecificity of Glucuronidation of Flavonoids. *J. Agric. Food Chem.* **2011**, *59* (13), 7452–7464. <https://doi.org/10.1021/jf1041454>.
- (21) Ebner, T.; Burchell, B. Substrate Specificities of Two Stably Expressed Human Liver UDP-Glucuronosyltransferases of the UGT1 Gene Family. *Drug Metab. Dispos.* **1993**, *21* (1), 50–55.
- (22) Tang, L.; Singh, R.; Liu, Z.; Hu, M. Structure and Concentration Changes Affect Characterization of UGT Isoform-Specific Metabolism of Isoflavones. *Mol. Pharm.* **2009**, *6* (5), 1466–1482. <https://doi.org/10.1021/mp8002557>.
- (23) Hanioka, N.; Naito, T.; Narimatsu, S. Human UDP-Glucuronosyltransferase Isoforms Involved in Bisphenol A Glucuronidation. *Chemosphere* **2008**, *74* (1), 33–36. <https://doi.org/10.1016/j.chemosphere.2008.09.053>.
- (24) Galijatovic, A.; Otake, Y.; Walle, U. K.; Walle, T. Extensive Metabolism of the Flavonoid Chrysin by Human Caco-2 and Hep G2 Cells. *Xenobiotica* **1999**, *29* (12), 1241–1256. <https://doi.org/10.1080/004982599237912>.
- (25) Walle, T.; Otake, Y.; Galijatovic, A.; Ritter, J. K.; Walle, U. K. Induction of UDP-Glucuronosyltransferase UGT1A1 by the Flavonoid Chrysin in the Human Hepatoma Cell Line Hep G2. *Drug Metab. Dispos.* **2000**, *28* (9), 1077–1082.
- (26) Iwuchukwu, O. F.; Ajetunmobi, J.; Ung, D.; Nagar, S. Characterizing the Effects of Common UDP Glucuronosyltransferase (UGT) 1A6 and UGT1A1 Polymorphisms on Cis- and Trans-Resveratrol Glucuronidation. *Drug Metab. Dispos.* **2009**, *37* (8), 1726–1732. <https://doi.org/10.1124/dmd.109.027391>.
- (27) Holmquist, G. L. Opioid Metabolism and Effects of Cytochrome P450. *Pain Med.* **2009**, *10* (suppl\_1), S20–S29. <https://doi.org/10.1111/j.1526-4637.2009.00596.x>.
- (28) Aprile, S.; Grosso, E. D.; Grosa, G. Identification of the Human UDP-Glucuronosyltransferases Involved in the Glucuronidation of Combretastatin A-4. *Drug Metab. Dispos.* **2010**, *38* (7), 1141–1146. <https://doi.org/10.1124/dmd.109.031435>.
- (29) Doerge, D. R.; Chang, H. C.; Churchwell, M. I.; Holder, C. L. Analysis of Soy Isoflavone Conjugation In Vitro and in Human Blood Using Liquid Chromatography-Mass Spectrometry. *Drug Metab. Dispos.* **2000**, *28* (3), 298–307.
- (30) Liang, S.-C.; Ge, G.-B.; Liu, H.-X.; Zhang, Y.-Y.; Wang, L.-M.; Zhang, J.-W.; Yin, L.; Li, W.; Fang, Z.-Z.; Wu, J.-J.; et al. Identification and Characterization of Human UDP-Glucuronosyltransferases Responsible for the In Vitro Glucuronidation of Daphnetin. *Drug Metab. Dispos.* **2010**, *38* (6), 973–980. <https://doi.org/10.1124/dmd.109.030734>.
- (31) Fernandes, I.; Marques, C.; Évora, A.; Cruz, L.; Freitas, V. de; Calhau, C.; Faria, A.; Mateus, N. Pharmacokinetics of Table and Port Red Wine Anthocyanins: A Crossover Trial in Healthy Men. *Food Funct.* **2017**, *8* (5), 2030–2037. <https://doi.org/10.1039/C7FO00329C>.
- (32) Zeng, X.; Shi, J.; Zhao, M.; Chen, Q.; Wang, L.; Jiang, H.; Luo, F.; Zhu, L.; Lu, L.; Wang, X.; et al. Regioselective Glucuronidation of Diosmetin and Chrysoeriol by the Interplay of Glucuronidation and Transport in UGT1A9-Overexpressing HeLa Cells. *PLOS ONE* **2016**, *11* (11), e0166239. <https://doi.org/10.1371/journal.pone.0166239>.
- (33) Itäaho, K.; Court, M. H.; Uutela, P.; Kostiainen, R.; Radominska-Pandya, A.; Finel, M. Dopamine Is a Low-Affinity and High-Specificity Substrate for the Human UDP-Glucuronosyltransferase 1A10. *Drug Metab. Dispos.* **2009**, *37* (4), 768–775. <https://doi.org/10.1124/dmd.108.025692>.
- (34) Lautala, P.; Ethell, B. T.; Taskinen, J.; Burchell, B. The Specificity of Glucuronidation of Entacapone and Tolcapone by Recombinant Human Udp-Glucuronosyltransferases. *Drug Metab. Dispos.* **2000**, *28* (11), 1385–1389.

- (35) Ghosal, A.; Hapangama, N.; Yuan, Y.; Achanfuo-Yeboah, J.; Iannucci, R.; Chowdhury, S.; Alton, K.; Patrick, J. E.; Zbaida, S. Identification of Human Udp-Glucuronosyltransferase Enzyme(s) Responsible for the Glucuronidation of Ezetimibe (Zetia). *Drug Metab. Dispos.* **2004**, *32* (3), 314–320. <https://doi.org/10.1124/dmd.32.3.314>.
- (36) Illingworth, N. A.; Boddy, A. V.; Daly, A. K.; Veal, G. J. Characterization of the Metabolism of Fenretinide by Human Liver Microsomes, Cytochrome P450 Enzymes and UDP-Glucuronosyltransferases. *Br. J. Pharmacol.* **2011**, *162* (4), 989–999. <https://doi.org/10.1111/j.1476-5381.2010.01104.x>.
- (37) Otake, Y.; Hsieh, F.; Walle, T. Glucuronidation versus Oxidation of the Flavonoid Galangin by Human Liver Microsomes and Hepatocytes. *Drug Metab. Dispos.* **2002**, *30* (5), 576–581. <https://doi.org/10.1124/dmd.30.5.576>.
- (38) Brand, W.; Boersma, M. G.; Bik, H.; Hil, E. F. H. den; Vervoort, J.; Barron, D.; Meinl, W.; Glatt, H.; Williamson, G.; Bladeren, P. J. van; et al. Phase II Metabolism of Hesperetin by Individual UDP-Glucuronosyltransferases and Sulfotransferases and Rat and Human Tissue Samples. *Drug Metab. Dispos.* **2010**, *38* (4), 617–625. <https://doi.org/10.1124/dmd.109.031047>.
- (39) Gagné, J.-F.; Montminy, V.; Belanger, P.; Journault, K.; Gaucher, G.; Guillemette, C. Common Human UGT1A Polymorphisms and the Altered Metabolism of Irinotecan Active Metabolite 7-Ethyl-10-Hydroxycamptothecin (SN-38). *Mol. Pharmacol.* **2002**, *62* (3), 608–617. <https://doi.org/10.1124/mol.62.3.608>.
- (40) Hanioka, N.; Ozawa, S.; Jinno, H.; Ando, M.; Saito, Y.; Sawada, J. Human Liver UDP-Glucuronosyltransferase Isoforms Involved in the Glucuronidation of 7-Ethyl-10-Hydroxycamptothecin. *Xenobiotica* **2001**, *31* (10), 687–699. <https://doi.org/10.1080/00498250110057341>.
- (41) Li, Y.; Lu, L.; Wang, L.; Qu, W.; Liu, W.; Xie, Y.; Zheng, H.; Wang, Y.; Qi, X.; Hu, M.; et al. Interplay of Efflux Transporters with Glucuronidation and Its Impact on Subcellular Aglycone and Glucuronide Disposition: A Case Study with Kaempferol. *Mol. Pharm.* **2018**, *15* (12), 5602–5614. <https://doi.org/10.1021/acs.molpharmaceut.8b00782>.
- (42) Picard, N.; Ratanasavanh, D.; Prémaud, A.; Meur, Y. L.; Marquet, P. Identification of the Udp-Glucuronosyltransferase Isoforms Involved in Mycophenolic Acid Phase II Metabolism. *Drug Metab. Dispos.* **2005**, *33* (1), 139–146. <https://doi.org/10.1124/dmd.104.001651>.
- (43) Jiang, W.; Hu, M. Mutual Interactions between Flavonoids and Enzymatic and Transporter Elements Responsible for Flavonoid Disposition via Phase II Metabolic Pathways. *RSC Adv.* **2012**, *2* (21), 7948–7963. <https://doi.org/10.1039/C2RA01369J>.
- (44) Hengstmann, J. H.; Goronzy, J. Pharmacokinetics Of<sup>3</sup>H-Phenylephrine in Man. *Eur. J. Clin. Pharmacol.* **1982**, *21* (4), 335–341. <https://doi.org/10.1007/BF00637623>.
- (45) Miksits, M.; Maier-Salamon, A.; Vo, T. P. N.; Sulyok, M.; Schuhmacher, R.; Szekeres, T.; Jäger, W. Glucuronidation of Piceatannol by Human Liver Microsomes: Major Role of UGT1A1, UGT1A8 and UGT1A10. *J. Pharm. Pharmacol.* **2010**, *62* (1), 47–54. <https://doi.org/10.1211/jpp.62.01.0004>.
- (46) Boersma, M. G.; van der Woude, H.; Bogaards, J.; Boeren, S.; Vervoort, J.; Cnubben, N. H. P.; van Iersel, M. L. P. S.; van Bladeren, P. J.; Rietjens, I. M. C. M. Regioselectivity of Phase II Metabolism of Luteolin and Quercetin by UDP-Glucuronosyl Transferases. *Chem. Res. Toxicol.* **2002**, *15* (5), 662–670. <https://doi.org/10.1021/tx0101705>.
- (47) Sun, D.; Jones, N. R.; Manni, A.; Lazarus, P. Characterization of Raloxifene Glucuronidation: Potential Role of UGT1A8 Genotype on Raloxifene Metabolism In Vivo. *Cancer Prev. Res. (Phila. Pa.)* **2013**, *6* (7), 719–730. <https://doi.org/10.1158/1940-6207.CAPR-12-0448>.
- (48) Krishnaswamy, S.; Duan, S. X.; Moltke, L. L. V.; Greenblatt, D. J.; Sudmeier, J. L.; Bachovchin, W. W.; Court, M. H. Serotonin (5-Hydroxytryptamine) Glucuronidation in Vitro : Assay Development, Human Liver Microsome Activities and Species Differences. *Xenobiotica* **2003**, *33* (2), 169–180. <https://doi.org/10.1080/0049825021000048809>.
- (49) Krishnaswamy, S.; Hao, Q.; Al-Rohaimi, A.; Hesse, L. M.; Moltke, L. L. von; Greenblatt, D. J.; Court, M. H. UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: II. Functional Impact of the Three Most Common Nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S). *J. Pharmacol. Exp. Ther.* **2005**, *313* (3), 1340–1346. <https://doi.org/10.1124/jpet.104.081968>.
- (50) Ishii, Y.; Koba, H.; Kinoshita, K.; Oizaki, T.; Iwamoto, Y.; Takeda, S.; Miyauchi, Y.; Nishimura, Y.; Egoshi, N.; Taura, F.; et al. Alteration of the Function of the UDP-Glucuronosyltransferase 1A Subfamily by Cytochrome P450 3A4: Different Susceptibility for UGT Isoforms and UGT1A1/7 Variants. *Drug Metab. Dispos.* **2014**, *42* (2), 229–238. <https://doi.org/10.1124/dmd.113.054833>.

- (51) Sten, T.; Bichlmaier, I.; Kuuranne, T.; Leinonen, A.; Yli-Kauhaluoma, J.; Finel, M. UDP-Glucuronosyltransferases (UGTs) 2B7 and UGT2B17 Display Converse Specificity in Testosterone and Epitestosterone Glucuronidation, Whereas UGT2A1 Conjugates Both Androgens Similarly. *Drug Metab. Dispos.* **2009**, *37* (2), 417–423. <https://doi.org/10.1124/dmd.108.024844>.
- (52) Brill, S. S.; Furimsky, A. M.; Ho, M. N.; Furniss, M. J.; Li, Y.; Green, A. G.; Green, C. E.; Iyer, L. V.; Bradford, W. W.; Kapetanovic, I. M. Glucuronidation of Trans-Resveratrol by Human Liver and Intestinal Microsomes and UGT Isoforms. *J. Pharm. Pharmacol.* **2006**, *58* (4), 469–479. <https://doi.org/10.1211/jpp.58.4.0006>.
- (53) Ruefer, C. E.; Gerhäuser, C.; Frank, N.; Becker, H.; Kulling, S. E. In Vitro Phase II Metabolism of Xanthohumol by Human UDP-Glucuronosyltransferases and Sulfotransferases. *Mol. Nutr. Food Res.* **2005**, *49* (9), 851–856. <https://doi.org/10.1002/mnfr.200500057>.